Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 75 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $202.73, for a total transaction of $15,204.75. Following the transaction, the executive vice president directly owned 16,431 shares in the company, valued at $3,331,056.63. This represents a 0.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Feld also recently made the following trade(s):

• On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $196.08, for a total value of $14,509.92.
• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $193.36, for a total value of $14,502.00.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $0.01 during midday trading on Wednesday, reaching $203.41. 385,345 shares of the company were exchanged, compared to its average volume of 1,691,664. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The business’s fifty day moving average is $197.87 and its two-hundred day moving average is $190.90. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The stock has a market cap of $57.95 billion, a PE ratio of 34.85, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. The company had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Analysts Set New Price Targets

BDX has been the topic of a number of research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Jefferies Financial Group lifted their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Piper Sandler raised their price target on Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $209.00.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board declared a quarterly dividend of $1.05 per share (payable March 31; record date March 10), implying a ~2.1% yield — supports income investors and signals cash‑flow confidence. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
• Positive Sentiment: Board authorized an additional $10M share buyback and the company says it has completed ~$250M of repurchases in FY26 to date — modest on a large market cap but signals management sees shareholder value in buybacks. RTT News – Stock Buybacks
• Positive Sentiment: Spin‑off of BD’s Biosciences & Diagnostic Solutions business is advancing: company set a February 5 record date and Waters shareholders approved the combination — this corporate‑restructuring could unlock value and reshape BD’s growth profile. BD Announces Record Date for the Spin-Off
• Positive Sentiment: Waters shareholders approved the combination with BD’s biosciences unit, removing a key approval hurdle and making the transaction timing clearer for investors. Waters Shareholders Approve Combination
• Positive Sentiment: Product and tech update — BD launched BD Research Cloud 7.0 with an AI-powered Horizon Panel Maker for advanced flow cytometry, supporting differentiation in lab workflow automation and data analytics. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: BD scheduled an audio webcast to announce Q1 FY2026 results — earnings and guidance will be the next major catalyst and could increase volatility. BD to Announce Financial Results for its First Quarter of Fiscal 2026
• Neutral Sentiment: Several analyst/feature pieces highlight BDX as a value and momentum name and compare it to peers — useful for sentiment but not new company fundamentals. Why Becton Dickinson (BDX) is a top value stock

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of institutional investors and hedge funds have recently bought and sold shares of BDX. Crux Wealth Advisors boosted its position in Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after buying an additional 49 shares during the period. Bill Few Associates Inc. raised its stake in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 55 shares during the last quarter. McElhenny Sheffield Capital Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 3.6% during the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 55 shares during the period. Gilbert & Cook Inc. grew its stake in shares of Becton, Dickinson and Company by 2.0% in the second quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after purchasing an additional 56 shares during the last quarter. Finally, Mendel Money Management increased its holdings in Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after purchasing an additional 58 shares during the period. 86.97% of the stock is owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.